NCT02869633 - Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 18, 2021

Study Completion Date

October 31, 2023

Conditions

Blastoid Variant Mantle Cell LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Hodgkin LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Follicular LymphomaRefractory Hodgkin LymphomaRefractory Mantle Cell Lymphoma

Interventions

DRUG

Ibrutinib

Given by mouth

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (5)

35233

University of Alabama at Birmingham Cancer Center, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

77030

M D Anderson Cancer Center, Houston

94304

Stanford Cancer Institute, Palo Alto

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER